Search - tctmd.com

Displaying 1 - 6 of 6

Sort: Relevancy | Date

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

FDA Approves Evinacumab for Rare Homozygous FH

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.